Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

Roland Buhl,1 Donald Banerji21Pulmonary Department, Mainz University Hospital, Mainz, Germany; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAbstract: Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antag...

Full description

Bibliographic Details
Main Authors:	Buhl R, Banerji D
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-10-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/profile-of-glycopyrronium-for-once-daily-treatment-of-moderate-to-seve-a11367

Similar Items

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
by: Buhl R, et al.
Published: (2014-03-01)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
by: D&rsquo;Urzo A
Published: (2013-08-01)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
by: Vincken W, et al.
Published: (2014-02-01)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
by: Wang C, et al.
Published: (2015-01-01)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
by: Sundeep Salvi, et al.
Published: (2022-01-01)

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
by: D'Urzo Anthony, et al.
Published: (2011-12-01)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
by: Mtibaa M, et al.
Published: (2021-12-01)

COPD and glycopyrronium responsiveness assessment: An appraisal
by: Parthasarathi Bhattacharyya, et al.
Published: (2023-01-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study
by: Hashimoto S, et al.
Published: (2016-10-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
by: Prakash A, et al.
Published: (2015-01-01)

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]
by: Hashimoto S, et al.
Published: (2017-01-01)

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis
by: Karabis A, et al.
Published: (2013-09-01)

A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
by: Lehmann S, et al.
Published: (2019-01-01)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01)

Glycopyrronium bromide is a new long-acting anticholinergic drug for the treatment of COPD
by: S. N. Avdeev, et al.
Published: (2014-12-01)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
by: Woodcock Ashley, et al.
Published: (2011-12-01)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
by: Donohue JF, et al.
Published: (2019-12-01)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
by: Claus F. Vogelmeier, et al.
Published: (2017-07-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
by: Holger Woehrle, et al.
Published: (2023-04-01)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
by: Ulrik CS
Published: (2012-09-01)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
by: Ulrik CS
Published: (2014-04-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
by: Dave Singh, et al.
Published: (2022-02-01)

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD
by: Ferguson GT, et al.
Published: (2018-03-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
by: Tara Rheault, et al.
Published: (2016-04-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
by: Marin JM, et al.
Published: (2016-06-01)

Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study
by: Kulich K, et al.
Published: (2015-01-01)

Glycopyrronium bromide: clinical efficacy and safety in patients with COPD (a review of clinical trials)
by: S. Y. Chikina, et al.
Published: (2015-12-01)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
by: Ismaila AS, et al.
Published: (2019-11-01)

Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults
by: Mula M
Published: (2013-05-01)

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
by: Fukushima Y, et al.
Published: (2018-04-01)

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups
by: Julie C Harper, et al.
Published: (2020-02-01)

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
by: Price, D, et al.
Published: (2011)